Medscape

About the Publication

The Journal's aim is rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. This includes clinical trials, outcomes research, clinical pharmacoeconomic studies, pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs, clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice and, in some instances, pharmacodynamic or pharmacokinetic studies in healthy volunteers, but in which some established or purported implications for clinical prescribing are discussed. In addition, short communications and case study reports that meet these criteria are also encouraged, as are letters to the editor. For further details, please contact us at clindruginvest@adis.co.nz. All manuscripts are subject to an objective and through evaluation by the technical adviser, followed by review by the International Editorial Board or other selected specialists.

Although great care has been taken in compiling the content of this publication, the publisher and its servants or agents are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not necessarily reflect the views of the Publisher, Editor, or Editorial Board.

Clinical Drug Investigation is published monthlyby Adis International Limited. For information on print subscriptions, electronic subscriptions, submission of manuscripts, and the editorial board, go to http://www.adis.com/journals/clinicaldruginvestigation/.

Copyright © 1996, 1997, 1998, 1999, 2000, 2001 Adis International Limited. All rights reserved throughout the world and in all languages. Viewing and printing of this Publication is for use by the subscriber only. No part of this publication may be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, including photocopying, recording, or through an information storage and retrieval system, without the written permission of the copyright holder. Details of terms and conditions and prices for electronic storage and redistribution (networking and extra terminals) are available from the Publisher. For customers within the United States, Canada, Central America or South America please contact mike.wisniewski@adis.com. For customers located in the Rest of the World, please contact steve.entwistle@adis.com

In addition to this the appearance of the code at the bottom of each page in this publication indicates the copyright owner's consent that copies of that page can be undertaken for personal or internal use of specific clients. This consent is given, however, on the condition that the copier pay the stated per copy fee to the Copyright Clearance Center Inc, 222 Rosewood Drive, Danvers, MA 01923, USA, for copying beyond that permitted by sections 107 and 108 of the US Copyright Law. This consent does not extend to other kinds of copying such as for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.